Notice détaillée
Titre
LBI
Formal Name (French)
Laboratoire de biomatériaux pour Immunoengineering
Formal Name (English)
Laboratory of Biomaterials for Immunoengineering
Lab Manager
Tang, Li
Group ID
U13294
Auteurs affilié
Ben Sayed, Nadia Yasmina
Bonati, Lucia
Enbar, Tom
Feng, Bing
Gao, Min
Guo, Yugang
Hu, Xiaomeng
Kurum, Armand
Lei, Kewen
Li, Rongrong
Li, Weilin
Liu, Yang
Navarro Suarez, Monica
Peng, Mei-Wen
Prange, Céline Jasmin
Rihtar, Erik
Tang, Li
Wang, Yi
Xie, Yuqing
Yu, Zheng
Zhang, Liwen
Zhao, Yang
Zhao, Yu
Zhou, Xiaolei
Bonati, Lucia
Enbar, Tom
Feng, Bing
Gao, Min
Guo, Yugang
Hu, Xiaomeng
Kurum, Armand
Lei, Kewen
Li, Rongrong
Li, Weilin
Liu, Yang
Navarro Suarez, Monica
Peng, Mei-Wen
Prange, Céline Jasmin
Rihtar, Erik
Tang, Li
Wang, Yi
Xie, Yuqing
Yu, Zheng
Zhang, Liwen
Zhao, Yang
Zhao, Yu
Zhou, Xiaolei
Institut
IBI-STI
Faculté
STI
Lien extérieur
http://tang-lab.epfl.ch/
Publications
A Magnetic Nanovaccine Enhances Cancer Immunotherapy
Central memory CD8+ T cells derive from stem-like Tcf7hi effector cells in the absence of cytotoxic differentiation
Delivery of mRNA for cancer therapy: progress and prospects
Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery
Materials Horizons Emerging Investigator Series: Li Tang, ecole polytechnique federale de Lausanne (EPFL), Switzerland
Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy
RNA-based nanomedicines and their clinical applications
Rational Design of Chemically Controlled Antibodies and Protein Therapeutics
Surgery-free injectable macroscale biomaterials for local cancer immunotherapy
Synthetic 3D scaffolds for cancer immunotherapy
Voir toutes les publications (73)
Central memory CD8+ T cells derive from stem-like Tcf7hi effector cells in the absence of cytotoxic differentiation
Delivery of mRNA for cancer therapy: progress and prospects
Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery
Materials Horizons Emerging Investigator Series: Li Tang, ecole polytechnique federale de Lausanne (EPFL), Switzerland
Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy
RNA-based nanomedicines and their clinical applications
Rational Design of Chemically Controlled Antibodies and Protein Therapeutics
Surgery-free injectable macroscale biomaterials for local cancer immunotherapy
Synthetic 3D scaffolds for cancer immunotherapy
Voir toutes les publications (73)
Le document apparaît dans
Authorities > Lab